CL2022001067A1 - Anticuerpos antihemaglutinina y métodos de uso de estos - Google Patents

Anticuerpos antihemaglutinina y métodos de uso de estos

Info

Publication number
CL2022001067A1
CL2022001067A1 CL2022001067A CL2022001067A CL2022001067A1 CL 2022001067 A1 CL2022001067 A1 CL 2022001067A1 CL 2022001067 A CL2022001067 A CL 2022001067A CL 2022001067 A CL2022001067 A CL 2022001067A CL 2022001067 A1 CL2022001067 A1 CL 2022001067A1
Authority
CL
Chile
Prior art keywords
antibodies
influenza
methods
bind
hemagglutinin
Prior art date
Application number
CL2022001067A
Other languages
English (en)
Spanish (es)
Inventor
Christos Kyratsous
Alina Baum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022001067A1 publication Critical patent/CL2022001067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
CL2022001067A 2019-10-28 2022-04-27 Anticuerpos antihemaglutinina y métodos de uso de estos CL2022001067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US202063094170P 2020-10-20 2020-10-20

Publications (1)

Publication Number Publication Date
CL2022001067A1 true CL2022001067A1 (es) 2023-01-27

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001067A CL2022001067A1 (es) 2019-10-28 2022-04-27 Anticuerpos antihemaglutinina y métodos de uso de estos

Country Status (13)

Country Link
US (2) US11773156B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051707A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220088446A (cg-RX-API-DMAC7.html)
CN (2) CN114761428B (cg-RX-API-DMAC7.html)
AU (2) AU2020374878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007923A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022001067A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005281A2 (cg-RX-API-DMAC7.html)
IL (1) IL292353A (cg-RX-API-DMAC7.html)
MY (1) MY207220A (cg-RX-API-DMAC7.html)
PH (1) PH12022550963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021086899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 B型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
HUE037659T2 (hu) * 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AU2015214146B2 (en) * 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016012530A (es) * 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MX389708B (es) * 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
AU2016270147B2 (en) 2015-06-03 2018-08-23 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
EP3471767A4 (en) * 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin

Also Published As

Publication number Publication date
BR112022007923A2 (pt) 2022-07-26
CN122521584A (zh) 2026-08-07
MY207220A (en) 2025-02-06
JP7611908B2 (ja) 2025-01-10
AU2025271140A1 (en) 2026-01-22
WO2021086899A1 (en) 2021-05-06
CO2022005281A2 (es) 2022-05-10
IL292353A (en) 2022-06-01
EP4051707A1 (en) 2022-09-07
KR20220088446A (ko) 2022-06-27
CA3153944A1 (en) 2021-05-06
CN114761428B (zh) 2026-05-22
US11773156B2 (en) 2023-10-03
JP2022553703A (ja) 2022-12-26
PH12022550963A1 (en) 2023-09-25
AU2020374878B2 (en) 2025-10-16
US20210171612A1 (en) 2021-06-10
US20240083983A1 (en) 2024-03-14
CN114761428A (zh) 2022-07-15
AU2020374878A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
CL2020000498A1 (es) Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920)
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
MX2019000761A (es) Anticuerpos anti-virus del zika y metodos de uso.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
AR103054A1 (es) Anticuerpos humanos para hemaglutinina influenza
AR104480A1 (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
EA202191973A3 (ru) Человеческие антитела к гликопротеину вируса эбола